<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356980</url>
  </required_header>
  <id_info>
    <org_study_id>060167</org_study_id>
    <secondary_id>06-C-0167</secondary_id>
    <secondary_id>NCI-P6062</secondary_id>
    <secondary_id>CYT-6091-06-01</secondary_id>
    <secondary_id>CDR0000486917</secondary_id>
    <nct_id>NCT00356980</nct_id>
    <nct_alias>NCT00328406</nct_alias>
  </id_info>
  <brief_title>TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects With Advanced Solid Organ Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune&#xD;
      system in different ways and stop tumor cells from growing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of TNF-bound colloidal&#xD;
      gold in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of TNF-bound colloidal gold (CYT-6091) in patients&#xD;
           with advanced solid tumors.&#xD;
&#xD;
        -  Determine the toxicities of CYT-6091 in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics of CYT-6091 in these patients.&#xD;
&#xD;
        -  Evaluate biopsy samples of tumor and adjoining normal tissue for levels of CYT-6091.&#xD;
&#xD;
        -  Determine if antitumor effects of CYT-6091 occur in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, sequential cohort, dose-escalation study.&#xD;
&#xD;
      Patients receive TNF-bound colloidal gold (CYT-6091) IV on days 1 and 15 (course 1).&#xD;
      Approximately 4-6 weeks later, patients are re-staged and responding patients may receive&#xD;
      another course of therapy. Patients may receive up to 3 re-treatment courses.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CYT-6091 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during the first course of therapy&#xD;
      for pharmacokinetic and pharmacodynamic analyses.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 4&#xD;
      months for the next year, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of TNF-bound colloidal gold (CYT-6091)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of CYT-6091</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of CYT-6091 in tumor biopsies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor biopsy histology and gene expression after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of CYT-6091</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electron microscopy of biopsy to determine presence of colloidal gold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of target and nontarget lesions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>colloidal gold-bound tumor necrosis factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
          -  Advanced and/or metastatic disease&#xD;
&#xD;
          -  Unresponsive to conventional therapy (i.e., disease progressed while receiving any&#xD;
             known standard curative or palliative therapy) OR previously untreated tumor for which&#xD;
             no standard treatment exists&#xD;
&#xD;
          -  Measurable or evaluable metastatic disease&#xD;
&#xD;
          -  No lymphoma or other hematologic malignancy&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Previously treated brain metastases with no evidence of recurrence allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Prothrombin time ≤ 1.5 times ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  LVEF ≥ 45% by echocardiogram or thallium stress test for patients &gt; 50 years of age or&#xD;
             history of cardiovascular disease&#xD;
&#xD;
          -  FEV_1 and DLCO &gt; 30% of predicted for patients with a history of pulmonary disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active bacterial or viral infection with systemic manifestations (e.g., fever,&#xD;
             symptoms, leukocytosis)&#xD;
&#xD;
               -  Localized chronic infections, such as mild acne or tinea pedis allowed&#xD;
&#xD;
          -  No acute or chronic viral hepatitis&#xD;
&#xD;
          -  No known bleeding disorder&#xD;
&#xD;
          -  No other concurrent life-threatening illness, including any of the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Severe oxygen-dependent chronic obstructive pulmonary disease&#xD;
&#xD;
               -  End-stage liver disease&#xD;
&#xD;
          -  No known active renal disease or renal insufficiency as evidenced by serum creatinine&#xD;
             &gt; 2.0 mg/dL&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 3 weeks since prior biological or cytotoxic agents (6 weeks for&#xD;
             nitrosoureas)&#xD;
&#xD;
          -  No known requirment for palliative treatment&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K. Libutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N, Tamarkin L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010 Dec 15;16(24):6139-49. doi: 10.1158/1078-0432.CCR-10-0978. Epub 2010 Sep 27.</citation>
    <PMID>20876255</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

